94 - Efficacy of SCY-247, a Second-generation Triterpenoid Antifungal, in Three Murine Models of Invasive Fungal Infections

Thursday, October 17, 2024

10:45 AM – 11:00 AM US PT

Location: 403 B

Co-Author(s)

SW

Steve Wring, PhD (he/him/his)

Pharmacology Translational Sciences Consultant
SCYNEXIS, Inc.
Jersey City, New Jersey, United States

Co-Author(s)

Katyna Borroto-Esoda, MS

Preclinical Consultant
SCYNEXIS, Inc.
Jersey City, New Jersey, United States
Nathan P. Wiederhold, PharmD

Professor
University of Texas Health San Antonio
San Antonio, TX, United States
Ashraf S. Ibrahim, PhD

Professor of Medicine
The Lundquist Institute at Harbor-UCLA Medical Center
Torrance, CA, United States

Presenting Author(s)

David A. Angulo, MD

Chief Executive Officer
SCYNEXIS, Inc.
Jersey City, NJ, United States

Slides

Disclosure(s):

Steve Wring, PhD: SCYNEXIS, Inc.: Advisor/Consultant

Katyna Borroto-Esoda, MS: Scynexis Inc: Advisor/Consultant

Nathan P. Wiederhold, PharmD: BioMerieux: Grant/Research Support; F2G: Advisor/Consultant, Grant/Research Support; Mycovia: Grant/Research Support; Scynexis: Grant/Research Support; Sfunga: Grant/Research Support

Ashraf S. Ibrahim, PhD: SCYNEXIS, Inc.: Advisor/Consultant, Grant/Research Support

David A. Angulo, MD: SCYNEXIS, Inc.: Board Member, SCYNEXIS, INC Officer and Board Member, SCYNEXIS Patents, Stocks/Bonds (Public Company)